San Diego-based Biocept Inc. has been on a roll this year to carve out a spot for itself in the emerging field of liquid biopsy and personalized medicine. A $10 million offering of common stock and warrants is the company's latest move to support its expanding menu of available companion tests for immuno-oncology therapeutics.